1. Home
  2. SBI vs RLYB Comparison

SBI vs RLYB Comparison

Compare SBI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.57

Market Cap

108.9M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$16.67

Market Cap

89.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBI
RLYB
Founded
1992
2018
Country
United States
United States
Employees
N/A
7
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.9M
89.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SBI
RLYB
Price
$7.57
$16.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
39.3K
15.4K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
6.16
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.73
Revenue Growth
N/A
43.00
52 Week Low
$7.52
$0.48
52 Week High
$8.01
$17.57

Technical Indicators

Market Signals
Indicator
SBI
RLYB
Relative Strength Index (RSI) 36.22 56.91
Support Level $7.53 $16.51
Resistance Level $7.88 $17.34
Average True Range (ATR) 0.04 0.46
MACD -0.00 -0.03
Stochastic Oscillator 0.00 37.65

Price Performance

Historical Comparison
SBI
RLYB

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: